General form of registration statement for all companies including face-amount certificate companies

Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details)

v3.24.3
Note 20 - Revision of Prior Period Financial Statements - Revised Consolidated Financial Statements (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2021
Accrued liabilities         $ 1,902 $ 855      
Total current liabilities $ 2,535   $ 2,535   2,532 2,361      
Total liabilities 2,535   2,535   2,532 2,361      
Accumulated deficit (83,299)   (83,299)   (76,624) (74,021)      
Total shareholders’ deficit 2,776 $ (1,028) 2,776 $ (1,028) 109 (2,226) $ (1,215) $ (1,729) $ (3,014)
Research and development expenses 878 392 1,517 712 741 1,299      
General and administration expenses 2,992 183 4,183 879 2,196 1,542      
Total operating expenses 4,301 670 6,673 1,990 3,576 3,444      
Loss before Income Tax (4,289) (650) (6,675) (1,526) (2,602) (3,904)      
Net Income (loss) $ (4,289) $ (650) (6,675) (1,526) (2,603) (3,904)      
Change in accrued liabilities         1,047 97      
Net cash used in operating activities     $ (4,937) $ (1,662) $ (2,172) (2,892)      
Previously Reported [Member]                  
Accrued liabilities           740      
Total current liabilities           2,246      
Total liabilities           2,246      
Accumulated deficit           (73,906)      
Total shareholders’ deficit           (2,111)      
Research and development expenses           1,272      
General and administration expenses           1,454      
Total operating expenses           3,329      
Loss before Income Tax           (3,789)      
Net Income (loss)           (3,789)      
Change in accrued liabilities           (18)      
Net cash used in operating activities           (2,892)      
Revision of Prior Period, Adjustment [Member]                  
Accrued liabilities           115      
Total current liabilities           115      
Total liabilities           115      
Accumulated deficit           (115)      
Total shareholders’ deficit           (115)      
Research and development expenses           27      
General and administration expenses           88      
Total operating expenses           115      
Loss before Income Tax           (115)      
Net Income (loss)           (115)      
Change in accrued liabilities           115      
Net cash used in operating activities           $ 0